News
Cadrenal Therapeutics Announces Exercise of Warrants for $4.7 Million Gross Proceeds
PONTE VEDRA, Fla., Nov. 1, 2024 /PRNewswire/ -- Cadrenal Therapeutics, Inc., ("Cadrenal" or the "Company") (Nasdaq: CVKD), a biopharmaceutical company developing tecarfarin, a late-stage novel oral and reversible anticoagulant (blood thinner) for certain rare medical...
Cadrenal Therapeutics Raises $5.1 Million via At-The-Market Facility
PONTE VEDRA, Fla., Oct. 24, 2024 /PRNewswire/ -- Cadrenal Therapeutics, Inc., (Nasdaq: CVKD) (the "Company" or "Cadrenal"), a late-stage biopharmaceutical company developing tecarfarin, a new vitamin K antagonist (VKA) designed to offer safer, superior chronic...
CADRENAL THERAPEUTICS JOINS CORPORATE COUNCIL OF ANTICOAGULATION FORUM
Participation Reinforces Cadrenal's Commitment to Innovation, Education and Improved Patient Outcomes with Anticoagulation Therapy PONTE VEDRA, Fla., Oct. 23, 2024 /PRNewswire/ -- Cadrenal Therapeutics, Inc. (Nasdaq: CVKD), a late-stage biopharmaceutical company...
Cadrenal Therapeutics to Participate in Lytham Partners Fall 2024 Investor Conference
PONTE VEDRA, Fla., Sept. 23, 2024 /PRNewswire/ -- Cadrenal Therapeutics, Inc., (Nasdaq: CVKD), a late-stage biopharmaceutical company developing tecarfarin, a new vitamin K antagonist (VKA) designed to be a superior and safer chronic anticoagulant for...
Cadrenal Therapeutics Announces Upcoming Type-B FDA Meeting in September to Discuss Tecarfarin Trial in LVAD Patients
PONTE VEDRA, Fla., Aug. 22, 2024 /PRNewswire/ -- Cadrenal Therapeutics, Inc. (Nasdaq: CVKD), a biopharmaceutical company developing tecarfarin, a late-stage, next-generation Vitamin K Antagonist (VKA) oral and reversible anticoagulant (blood thinner) designed to...
Published Findings Highlight Tecarfarin’s Potential and Reinforce Need for Better Anticoagulation Therapy in LVAD Patients
Analysis features the growing need to evolve anticoagulation therapy beyond warfarin to avoid gastrointestinal bleeding, a significant and common complication for left ventricular assist device (LVAD) patients resulting in expensive hospitalizations Tecarfarin, a...
Cadrenal Therapeutics to Present at Upcoming Investor Conferences
PONTE VEDRA, Fla., Aug. 14, 2024 /PRNewswire/ -- Cadrenal Therapeutics, Inc., (Nasdaq: CVKD), a biopharmaceutical company developing tecarfarin, a late-stage, next-generation Vitamin K Antagonist (VKA) oral and reversible anticoagulant (blood thinner) designed to...
Cadrenal Therapeutics Provides Second Quarter 2024 Corporate Update
PONTE VEDRA, Fla., Aug. 7, 2024 /PRNewswire/ -- Cadrenal Therapeutics, Inc., (Nasdaq: CVKD), a biopharmaceutical company developing tecarfarin, a late-stage, next-generation Vitamin K Antagonist (VKA) oral and reversible anticoagulant (blood thinner) designed to...
Cadrenal Therapeutics and Abbott Initiate Collaborative Effort to Advance Novel Anticoagulant Tecarfarin for Patients with LVADs
PONTE VEDRA, Fla., Aug. 6, 2024 /PRNewswire/ -- Cadrenal Therapeutics, Inc., (Nasdaq: CVKD), a biopharmaceutical company developing tecarfarin, a late-stage, new-generation Vitamin K Antagonist (VKA) oral and reversible anticoagulant (blood thinner) designed to...
Cadrenal Therapeutics to Present at the Emerging Growth Conference on July 18, 2024
PONTE VEDRA, Fla., July 17, 2024 /PRNewswire/ -- Cadrenal Therapeutics, Inc., (Nasdaq: CVKD), a biopharmaceutical company developing tecarfarin, a late-stage, new-generation Vitamin K Antagonist (VKA) oral and reversible anticoagulant (blood thinner) designed to...